Blueprint partners up with a degrader-focused 'vant' as part of pipeline-boosting campaign
Part of Vivek Ramaswamy and Matt Gline’s expansive universe of “vants,” the little-known degrader play Proteovant has silently been chipping away for more than a year. Now, Blueprint Medicines will take a bet on that biotech and its AI-focused sister firm.
Blueprint will pay $20 million upfront and a potential $632 million in additional downstream milestones for two protein degrader programs from Proteovant with the option to add two more programs to the slate, the partners said Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.